Skip to main content

Table 1 Subject demographics, neuropsychological, and clinical data

From: Effects of gene mutation and disease progression on representative neural circuits in familial Alzheimer’s disease

 

Control (n = 102)

PMC (n = 40)

SMC (n = 30)

P value PMC vs. Control

P value SMC vs. PMC

Age (years)

44.4 (12.6)

36.3 (15.7)

50.5 (9.4)

0.002**

< 0.001***

Sex (male/female)

37/65

14/26

18/12

0.887

0.038#

Education (years)

11.0 (5.3)

12.1 (4.1)

10.5 (4.2)

0.249

0.118

EYO (years)

N/A

−11.6 (13.2)

4.1 (3.1)

 

< 0.001***

MMSE

29.0 (1.6)

28.8 (1.8)

16.5 (8.0)

0.498

< 0.001***

MoCA

27.1 (2.3)

27.1 (3.0)

12.7 (7.7)

0.872

< 0.001***

CDR

N/A

N/A

1.3 (0.8)

  

Subject numbers

APP/PS1/PS2

N/A

17/21/2

9/18/3

 

0.474

APOEε4 (Y/N)

26/76

8/32

10/20

0.490

0.207

 T1 MRI after PP

95

40

28

  

 DTI after QC+PP

45

24

9

  

 rsfMRI after QC+PP

84

30

19

  
  1. For continuous variables, data are shown in mean (SD), and the independent sample t-test was used for group comparison; for categorical variables, the chi-square test was used for group comparison. Bonferroni correction was used to correct for multiple comparison. #0.025 < P < 0.05, **0.001 < P < 0.01, ***P < 0.001
  2. Y/N the number of subjects carrying (Y) or not carrying (N) APOEε4, PP preprocessing, QC quality control, PMC presymptomatic mutation carriers, SMC symptomatic mutation carriers, EYO estimated years from symptom onset, MMSE Mini-Mental State Examination, MoCA Montreal Cognitive Assessment, CDR Clinical Dementia Rating scale